(Total Views: 622)
Posted On: 01/21/2021 8:01:29 AM
Post# of 149195
Faulty reasoning:
"CytoDyn, with it’s lead drug leronlimab, is the only company to successfully complete a Phase 3 randomized clinical trial for severe-to-critically ill Covid-19 patients with mortality as an endpoint!!! You don’t have to be a virologist to know that a drug with a mortality as a primary endpoint completes two DSMC reviews with no changes, to know that means the drug is working as it was intended in the trial design."
Read More: https://investorshangout.com/post/view?id=602...z6kBe7oKJM
"CytoDyn, with it’s lead drug leronlimab, is the only company to successfully complete a Phase 3 randomized clinical trial for severe-to-critically ill Covid-19 patients with mortality as an endpoint!!! You don’t have to be a virologist to know that a drug with a mortality as a primary endpoint completes two DSMC reviews with no changes, to know that means the drug is working as it was intended in the trial design."
Read More: https://investorshangout.com/post/view?id=602...z6kBe7oKJM
(4)
(1)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼
